30 Day
Magnesium Supplementation for Anxiety Reduction
STUDY TITLE | Magnesium Supplementation for Anxiety Reduction |
---|---|
Submitted under umbrella | |
Date submitted |
- |
End date |
There is no pre-specified end date and sub-studies remain open long-term. |
Language |
English |
Efforia AI IRB approval recommendation | |
Recruitment page preview | |
Author edit | |
Informed consent |
|
Study author |
|
Principal investigator |
Matthew Amsden |
Sub-Investigator for Adverse Events |
Dr. Viral Patel |
Description |
Participants will undergo a regimen of daily magnesium supplementation aimed at reducing symptoms of anxiety, stress, and depression. The protocol begins with a baseline assessment using the DASS-21 survey, followed by a specified period of supplementation, and concludes with a post-treatment DASS-21 survey to evaluate changes. |
Participant engagement length |
30 Days |
Sponsor |
This study is made possible by your payment to cover all supplies and expenses required to participate. |
Cost to participant |
$0 |
Included products & services |
Product or Service Missing from Efforia Library: $0
: $0
|
Outcome measures |
PHQ-8 |
Methodology |
Single Arm longitudinal where participants act as their own control |
Basic or advanced dissemination plan |
Basic |
Deviation from recruitment approach |
No |
Deviation from statistical approach |
No |
Will study include “more about you questions” |
Yes |
Recruitment jurisdictions |
United States, United Kingdom |
Clinicaltrials.Gov |
Yes |
Committment to list findings on clinicaltrials.Gov |
Yes |
This document is prepared with the assistance of AI, but is reviewed by a human.
Rational & Study Design
Why I created this challenge:
Amidst rising global anxiety, magnesium's role in mental health has sparked both scholarly debate and social media buzz. Research suggests magnesium may alleviate anxiety and depression symptoms, yet public discourse often outpaces scientific consensus. This disparity necessitates rigorous evaluation. This challenge aims to bridge this gap, providing evidence on magnesium’s efficacy in reducing anxiety, stress, and depression, crucial for informed health decisions.
My Objective for You:
Your goal is to systematically assess how daily magnesium supplementation influences your anxiety and depression levels, using the DASS-21 survey. This protocol is crafted to not only contribute to broader research but also empower you with personal insights into managing anxiety.
Aims & Objectives:
The primary aim is to evaluate the effect of daily magnesium supplementation on anxiety, stress, and depression levels in participants. Secondly, this challenge seeks to increase participant awareness and self-management of mental health through structured supplementation.
Significance & Impact:
This challenge holds significant potential to impact public health by scientifically validating magnesium's role in mental wellness. Expected outcomes include improved participant mental health and robust data contributing to global mental health practices. Limitations include variability in individual absorption rates and dietary differences affecting magnesium efficacy.
The Intervention
Included Products & Services
Product Name: Product or Service Missing from Efforia Library
Quantity included:
Price: $0.00
Product Description:
Product Image:
Ingredients:
Product Safety:
Product Name:
Quantity included:
Price: $0.00
Product Description:
Product Image:
Ingredients:
Product Safety:
Study Design & Methodology
Inappropriate Participants & Inclusion/Exclusion
Study Design & Experience
Statistical Analysis Plan
Limitations & Justification
Human Subjects Ethics
Suitability Under Minimal Risk Umbrella Protocol
Suitability for Pay to Participate Model
Human Subjects Protection Questionnaire
Logging
Logging
Date | Event | Message | Name |
---|---|---|---|
No records found. |